Newly Launched Replay Has Big Plans For Writing and Delivering ‘Big DNA’

Viral Vector Has 30 Times Capacity Of AAV

 
• By Andrew McConaghie

With a hub-and-spoke model, Replay has ambitious plans to solve multiple problems in genetic medicine and to disrupt the current AAV gene therapy model.

Herpes Simplex
One of the company's key technologies is a herpes simplex virus based gene therapy. • Source: Shutterstock

More from Business

More from Scrip